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Abstract
Background: Ebola virus is the causative agent of a severe syndrome in humans with a fatality rate that can approach
90 %. During infection, the host immune response is thought to become dysregulated, but the mechanisms through
which this happens are not entirely understood. In this study, we analyze RNA sequencing data to determine the host
response to Ebola virus infection in circulating immune cells.
Results: Approximately half of the 100 genes with the strongest early increases in expression were interferon-
stimulated genes, such as ISG15, OAS1, IFIT2, HERC5, MX1 and DHX58. Other highly upregulated genes included
cytokines CXCL11, CCL7, IL2RA, IL2R1, IL15RA, and CSF2RB, which have not been previously reported to change
during Ebola virus infection. Comparing this response in two different models of exposure (intramuscular and
aerosol) revealed a similar signature of infection. The strong innate response in the aerosol model was seen not
only in circulating cells, but also in primary and secondary target tissues. Conversely, the innate immune response
of vaccinated macaques was almost non-existent. This suggests that the innate response is a major aspect of the
cellular response to Ebola virus infection in multiple tissues.
Conclusions: Ebola virus causes a severe infection in humans that is associated with high mortality. The host
immune response to virus infection is thought to be an important aspect leading to severe pathology, but the
components of this overactive response are not well characterized. Here, we analyzed how circulating immune
cells respond to the virus and found that there is a strong innate response dependent on active virus replication.
This finding is in stark contrast to in vitro evidence showing a suppression of innate immune signaling, and it
suggests that the strong innate response we observe in infected animals may be an important contributor to
pathogenesis.
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Background
Ebola virus belongs to the family Filoviridae and is an
envelope, non-segmented, negative-stranded RNA
virus with filamentous virion morphology. Infection
with Ebola virus causes Ebola Virus Disease, a disease
associated with mortality rates between 25 and 90 %
[1]. The earliest clinical symptoms are non-specific
and flu-like, such as high fever, headache and myalgia
[1–3]. During the large outbreak in West Africa (2014-
present), the symptoms also included diarrhea and
vomiting [2]. The late stage of disease is associated
with immune cell imbalances such as neutrophilia and
coagulation disorders like diffuse intravascular coagu-
lopathy [4–6].
It has been postulated that survival following Ebola
virus infection correlates with the ability of the host to
mount an early and robust interferon response. In cul-
tured human liver cells, the virus has been shown to
block specific aspects of the innate immune response,
preventing the expression of interferon-stimulated genes
[7, 8]. Experiments in animal models, including mice [9,
10] and guinea pigs [11], have provided evidence that
the suppression of interferon signaling is important for
pathogenesis.
Previous studies of primates exposed to wild-type
Ebola virus strains have suggested that there is a strong
interferon-like transcription signal in circulating im-
mune cells [12]. It has not yet been established
whether interferon signaling is seen only in circulating
immune cells or whether there is evidence for
interferon-induced mRNA expression in infected tis-
sues as well. It is also not well established whether this
response is dependent on active virus replication. Sev-
eral studies have reported that during infections
caused by respiratory and hemorrhagic fever viruses,
circulating immune cells undergo major gene regula-
tory changes that result in the upregulation of many
innate immune system genes [13–16]. One of the most
interesting aspects about this surge in transcriptional
activity is that it constitutes an early measurable indi-
cator of infection.
In the present study, we studied the transcriptional
profile of circulating immune cells obtained from sev-
eral different studies. We investigated the most ro-
bustly expressed genes that were observed in the
peripheral blood mononuclear cells (PBMCs) of cyno-
molgus macaques following different routes of infec-
tion (aerosol and intramuscular), as well as following
vaccination of the host. We further investigated
whether genes highly-upregulated in PBMCs also
showed changes in expression in tissues of infected an-
imals. Our results suggest that interferon-signaling is




Macaque model of intramuscular exposure to Ebola virus
This RNA sequencing study used cynomolgus macaques
divided in two groups: vaccinated and Ebola-naïve [17].
The vaccinated group received an intramuscular injec-
tion of recombinant Vesicular Stomatitis Virus with the
Ebola glycoprotein (rVSV/EBOV-GP) and a lethal dose
of EBOV strain Kikwit several days later. The Ebola-
naïve group was treated with a non-protective dose of
rVSV/MARV-GP and received the same lethal dose of
EBOV administered to the vaccinated group several days
later. Blood samples were taken at 0, 4 and 7 days post-
infection (see Table 1). PBMCs were isolated from the
18 blood samples, and RNA sequencing was performed
using the same methods specified in [18].
Macaque model of aerosol exposure to Ebola virus
This study used rhesus macaques exposed to EBOV via
aerosol (between 7.43×102 and 2.74×102 plaque-forming
units (PFU)) 12 PBMC samples were collected at 0, 3, 6
and 8 days post-infection (see Table 1 for details) [19].
19 spleen samples were obtained at 0, 1, 3, 4, 5, 6, 7 and
8 dpi. 12 adrenal gland samples were obtained at 1, 3, 4,
6, 7 and 8 dpi. 8 axillary lymph node samples were ob-
tained at 0, 1, 3, 4, 5 and 6 dpi. 11 brain samples were
obtained at 1, 3, 4, 6 and 7 dpi. 4 liver samples were ob-
tained at 0, 3, 5 and 8 dpi. 3 pancreas samples were ob-
tained at 0, 4 and 8 dpi. RNA was extracted from
PBMCs and the other tissues and sequenced [20, 21].
For tissue homogenates, RNA was extracted from
TRIzol-inactivated samples using BCP:chloroform, and
total RNA was depleted of small RNAs (<200 nt) with a
mirVana miRNA Isolation Kit per manufacturer’s in-
structions (Thermo Fisher, Waltham MA). Subsequently,
ribosomal RNA was depleted using complementary
DNA oligos and RNase H. For PBMC samples, mRNA
was enriched using the Dynabeads mRNA Purification
Kit (Thermo Fisher) per protocol. For all samples, Tru-
Seq v2 (Illumina, San Diego CA) libraries were con-
structed as described previously [20, 22], multiplexed
using custom adaptors [20], and sequenced on a HiSeq
to obtain 2 × 100 bp paired-end reads. Reads were
demultiplexed with a 0 mismatch tolerance, and cross-
sample contamination was back-calculated from syn-
thetic RNAs that were spiked in prior to library
construction [22]. The PBMC samples referenced above,
as well as 24 additional PBMC samples taken at 0, 1, 3,
4, 5, 6, 7 and 8 dpi (Table 1), were also quantified using
microarrays according to the methods specified in [23].
Mouse model of exposure to Ebola virus
This study used BALB/c mice divided into two groups
[9]. One group was inoculated intraperitoneally with
Caballero et al. BMC Genomics  (2016) 17:707 Page 2 of 13
wild-type EBOV. The other group was inoculated with
mouse-adapted EBOV. Spleen samples were collected
and homogenized at 0, 12, 24, 48 and 72 h post-
infection for both groups (see Table 1). RNA was
extracted from the 29 spleen samples and Agilent micro-
array processing was performed as described in [9].
Macaque model of aerosol exposure to Lassa and Marburg
virus
This study used cynomolgus macaques divided in two
groups [24]. One group was exposed to LASV Josiah
and the other to MARV Angola, both groups received
1000 PFU of virus via aerosol. RNA was extracted from
24 PBMC samples (see Table 1) and RNA sequencing
was performed.
Fold change analysis of sequencing data
After the raw sequencing reads of each study were gen-
erated, they were trimmed and the adapters were re-
moved using Trimmomatic [25]. The processed reads
were aligned to the Macaca mulatta genome (Ensembl
release 77) [26] using TopHat 2.0.11 [27] with default
parameters (segment length of 25, allowing up to 2 seg-
ment mismatches). Gene counts were obtained using
HTSeq [28] to count reads that aligned uniquely to each
gene. Counts were normalized to compensate for differ-
ences in library size using the trimmed mean of M-
values normalization method included in the edgeR
BioConductor package [29].
A gene was deemed to show statistically significant
changes in expression at a specific time after infection if
the moderated t-test between the infected and pre-
infection samples resulted in a p-value lower than 0.05
(after Benjamini-Hochberg correction), with an absolute
fold change in expression greater or equal to 3, and an
average number of reads across all samples greater than
4 counts per million (CPM). When calculating relative
changes to the pre-infection samples, infected samples
were not subtracted from their individual uninfected
controls (since not every infected sample had a pre-
infected control), but from an average of all the pre-
infection samples. Statistical significance, however, was
calculated using the individual pre-infection samples,
not their average.
Fold change analysis of microarray data
Agilent two-color human gene expression microarrays
were processed using limma [30]. Fold changes were ob-
tained by calculating the log-ratio between the inten-
sities of the red channel (corresponding to experimental
Table 1 Summarizes the datasets described below
Study Ref. Tissue Group Platform Num. animals Num. samples Timepoints (samples/timepoint)
Macaque model of intramuscular
exposure to Ebola virus
[17] PBMC rVSV/EBOV-GP
(vaccinated)
RNAseq 9 9 0, 4, 7 dpi (n = 3)
rVSV/MARV-GP
(Ebola-naïve)
RNAseq 9 9 0, 4, 7 dpi (n = 3)
Macaque model of aerosol
exposure to Ebola virus
[19] PBMC EBOV RNAseq 8 12 0 (n = 4), 1 (n = 2), 3 (n = 2),
6 (n = 2), 8 (n = 2) dpi
Microarray 14a 36a 0 (n = 18), 1 (n = 2), 3 (n = 2),
4 (n = 4), 5 (n = 4), 6 (n = 2),
7 (n = 2), 8 (n = 2) dpi
Spleen RNAseq 19 19 0 (n = 2), 1 (n = 3), 3 (n = 3),
4 (n = 2), 5 (n = 2), 6 (n = 2),
7 (n = 3), 8 (n = 2) dpi
Adrenal gland 12 12 1 (n = 2), 3 (n = 1), 4 (n = 2),
6 (n = 1), 7 (n = 3), 8 (n = 2) dpi
Lymph node 6 6 0, 1, 3, 4, 5, 6 dpi (n = 1)
Brain 10 10 1, 3, 4, 6, 7 (n = 2)
Liver 4 4 0, 3, 5, 8 dpi (n = 1)
Pancreas 3 3 0, 4, 8 dpi (n = 1)
Mouse model of exposure to
Ebola virus
[9] Spleen WT-EBOV Microarray 15 15 0 (n = 2), 12 (n = 4), 24 (n = 3),
36 (n = 3), 48 (n = 3) hpi
MA-EBOV 14 14 0 (n = 2), 12 (n = 3), 24 (n = 3),
36 (n = 3), 48 (n = 3) hpi
Macaque model of aerosol
exposure to Lassa and
Marburg virus
[24] PBMC LASV RNAseq 7 12 0 (n = 4), 3 (n = 4), 6 (n = 2),
10 (n = 2) dpi
9 12 0, 3, 5, 9 dpi (n = 3)
a 8 of these animals (and 12 of these samples) correspond to the 8 animals (and 12 samples) that were quantified using RNA sequencing)
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samples) and the green channel (corresponding to Hu-
man Universal Reference RNA [31]). These were later
background-corrected and normalized using the LOESS
algorithm. Agilent one-color mouse gene expression mi-
croarrays were processed in a similar manner as the
two-color arrays, but using the reported expression value
for each probe instead of the log-ratio between the two
channels. Benjamini-Hochberg was used to correct the
false discovery rate of multiple testing.
Results
To examine the response of the circulating immune sys-
tem of nonhuman primates infected with Ebola virus, we
used sequencing data from PBMCs of cynomolgus ma-
caques infected with Ebola virus via intramuscular injec-
tion. These included pre-infection samples and samples
taken 4 and 7 days after infection, as described in [17,
18] (unless specified otherwise, results and figures dis-
cussed in this manuscript refer to this dataset). We were
first interested in connecting the transcriptomic data to
previously reported information about the host cytokine
response to Ebola virus infection and to examine
whether other cytokines showed evidence of being up-
regulated during infection.
Cytokine responses during Ebola virus infection
Previous studies have shown strong increases in cytokine
protein levels in the serum of infected animals and
humans [32–34]. In our analysis, we observe that a subset
of these cytokines reported to be present in the serum also
show transcriptional upregulations in PBMCs by 4 days
post-infection (IL6, IL1B, IL1RN, CCL8, CXCL10) and by
7 days post-infection (CCL2, CCL3, CSF1, TNF, CXCL1,
FAS and CXCL8). Figure 1a shows the average fold-
change (log2) for each of these cytokines on the y-axis, as
well as the time after infection when the samples were
taken on the x-axis. These results suggest a biphasic im-
mune response to infection. IL1B is the only cytokine with
an unusual transcription pattern, peaking at day 4 and
returning to pre-infection levels by day 7.
Additionally, we identified several cytokines that were
not previously known to play a role during Ebola virus
infection. Among these, some became upregulated dur-
ing the early stage of infection (day 4) CCL7, CXCL11,
IL1R1 (cytokine receptor) and IL15RA, and others be-
came upregulated during the late stage of infection (day
7): IL2RA, CSF2RB and others (Fig. 1b).
The majority of cytokines during Ebola virus infection
in vaccinated animals did not reach a 3-fold change in ex-
pression at 4 or 7 days post-infection. Three notable ex-
ceptions were CCL7, CXCL10 and CXCL11, which
peaked (respectively) at 42.8, 35.5 and 6.6 times the level
of expression at 7 days post-infection compared to the
pre-infection levels. These genes mirrored the expression
patterns seen in the Ebola-naïve animals, but at a lower
magnitude (Fig. 2). For example, by 4 days post-infection
the expression level of CXCL10 had gone up 7.1-fold in
the Ebola-naïve group, but only 3.1-fold in the vaccinated
group. By 7 dpi, these values were 92.6-fold in the Ebola-
naïve group and 35.5-fold in the vaccinated group.
A strong and sustained early host transcriptional
response after Ebola virus infection contains many genes
associated with the innate immune response
We also analyzed the macaque intramuscular Ebola data-
set to identify genes that underwent strong, statistically-







































































Fig. 1 Changes in expression of cytokines during Ebola virus infection. Lines represents the average fold-change in expression (log2, y-axis) of
each cytokine gene at different times (x-axis) after Ebola virus infection. Panel a shows twelve cytokines that undergo strong transcriptional
changes and that were previously reported to experience changes in serum concentration during Ebola virus infection. IL1B (dashed stroke)
shows a transient level of expression, peaking at 4 dpi. Panel b shows six cytokines that follow similar patterns of expressions to those in Panel
(a) but that have not been previously reported to play a role during Ebola virus infection
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significant increases in expression between pre-infection
and 4 days post-infection. The thresholds that we used
were 8 or higher fold-change with at least 4 read counts
per million, and an adjusted p-value of less than 0.05.
We found 125 genes that met these requirements, 25 of
which showed levels of expression that peaked at 4 days
post-infection and decreased by 7 dpi. The levels of ex-
pression of the other 100 genes remained constant or
increased between days 4 and 7. Of these, 33 genes are
known to be responsive to innate immunity transcrip-
tion factors such as IRF3, IRF7 and STAT1 (also known
as interferon-stimulated genes, or ISGs) [35, 36]
(Fig. 3a) and are herein referred to as canonical ISGs.
Figure 3a shows the log2-fold change of these
interferon-stimulated genes at 0, 4 and 7 days post-
infection, highlighting a few representative examples
(MX1, ISG15, OAS1, DHX58 (RIG-I), IFIT2, and
HERC5). The other 47 strong and sustained genes show
similar responses to the ISG group but they have not
been previously identified as downstream effectors of
the interferon response (Fig. 3b). This population
includes several neutrophil-associated genes (OLFM4,
CD177, SERPINB1, S100P, PTX3 and MMP8),
suggesting that there is an accumulation of neutrophils
in PBCMs during the course of infection.
The strong increase in canonical ISGs following Ebola
virus infection led us to investigate if this strong
interferon-like response was observed in other animal
models of Ebola virus infection. To do this, we used the
Ebola mouse model dataset to analyze the ISG response
in mice that had been infected with wild type EBOV
(which is non-pathogenic in mice) and mouse-adapted
EBOV (which is pathogenic in mice) [9]. Interestingly,
we found that a strong ISG response was apparent 3 days
after infection in mice that were infected, irrespective of
pathogenesis (Fig. 4).
We validated these results using expression data from
two previous studies that infected rhesus macaques with
Ebola virus (intramuscular injection) and treated them
with an anticoagulant drug (recombinant human acti-
vated protein C (rhAPC), and recombinant nematode
anticoagulant protein c2 (rNAPc2) [37, 38]). We found
significant similarity for a majority of early response
genes even though the expression data was quantified
using microarrays. For example, in the rhAPC samples,
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Fig. 2 Effects of vaccination in the expression of cytokines after Ebola virus infection. Each line represents the log2 fold-change (y-axis) of three
cytokines that become upregulated in vaccinated animals: CCL7, CXCL10, and CXCL11 at different times (x-axis) after Ebola virus infection. IL6 is
shown to illustrate the behavior of a cytokine that only becomes expressed in Ebola-naïve animals
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log2-fold at 3 and 6 days post-infection, respectively; in
the rNAPc2 samples the increases were 4.6 log2-fold
and 6.9 log2-fold at 3 and 6 days post-infection, respect-
ively. Additionally, we were also able to confirm these
patterns in a previous study that quantified PBMC sam-
ples from Ebola virus-infected macaques using microar-
rays [12]. In this dataset, for example, IFIT2 expression
increases 3.4 log2-fold 3 dpi and remains sustained
throughout infection. The fact that this multiple tran-
scriptomic studies agree on this observation provides
additional evidence that the innate immune signaling is
upregulated after infection.
The sustained transcription of early responsive genes is
not present in a non-productive infection
Given the repeated appearance of a type I interferon-like
signature following Ebola virus infection, we were inter-
ested in determining whether the appearance of an early
innate immune response following a hemorrhagic fever
virus infection was a response to the injection of a
negative strand RNA virus. To do this, we used the
intramuscular Ebola dataset to compare the innate im-
mune response to Ebola virus in non-human primates
that had been previously vaccinated against Ebola virus
to those that had been immunized against a different
hemorrhagic fever virus and were therefore susceptible
to Ebola virus (Ebola-naïve group) [17, 18]. Figure 5
shows the changes in expression of four ISGs that illus-
trate the overall differences in response between the two
animal cohorts. In the Ebola-naïve group, for example,
SIGLEC1 undergoes a 5.72 log2-fold change 4 days post-
infection, while in the vaccinated group the change is
only 2.53 log2-fold change (Fig. 5a). By 7 days post-
infection the difference is even greater: 7.64 in the
Ebola-naïve group, and 3.36 in the vaccinated group. A
similar trend was seen for RSAD2, MX1, IFIT3, and the
majority of genes making up the early transcriptional
response: vaccinated animals showed significantly lower
levels of expression than Ebola-naïve animals. These
results argue that the strong interferon-like response is
the result of active virus dissemination, and is not a
non-specific response to the injection of viral material.





















Fig. 4 Expression of interferon stimulated genes in spleens of Ebola virus infected mice. Each line represents the average fold-change in expression
(log2, y-axis) of each gene at different times (x-axis) after Ebola virus infection, for each of the conditions: uninfected control, non-pathogenic wild-type
Ebola virus infection, and pathogenic mouse-adapted Ebola virus infection


















































Fig. 3 Host genes showing strong and sustained changes in expression early after Ebola virus infection. Each line represents the average fold-change
in expression (log2, y-axis) of each gene at different times (x-axis) after Ebola virus infection. Panel a shows canonical interferon-stimulated genes while
panel b shows other strong and sustained genes. A representative sample of genes is shown in black to illustrate the individual patterns of expression
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The early transcriptional response is common to multiple
hemorrhagic fevers
The early host transcriptional response that we observed
in these studies appeared to be similar to strong innate
transcriptional responses observed in other hemorrhagic
fevers [24]. To compare these responses, we used gene
expression data from cynomolgus macaques exposed via
aerosol to either Lassa virus [24, 39] or Marburg virus
[24, 40], and found that the innate response to both in-
fections is highly similar to that of Ebola virus infection.
This is illustrated in Fig. 6, which shows the changes in
expression of four canonical ISGs (MX1, ISG15, DHX58
and OAS1) during Ebola, Lassa, and Marburg virus
infection. All four genes are significantly upregulated at
the earliest infected timepoint, and they remain sus-
tained throughout the late stage of disease. For example,
MX1 goes up 4.7 log2-fold 3 days after Lassa infection,
4.1 log2-fold 3 days after Marburg infection, and 4.9
log2-fold 4 days after Ebola virus infection. By 6–7 days
post-infection, the log2-fold changes are 6.1, 6, and 5.4,
respectively. By 9–10 days post-infection, the expression
of MX1 seems to decrease mildly in Lassa and Marburg
infection, but it remains at very high levels compared to
the pre-infection baseline. During Lassa infection, ISG15
and OAS1 undergo similar expression changes to those
of MX1: a strong increase, followed by a slight decrease
in expression. For Marburg and Ebola virus infection,
the early levels of expression of these genes increase
more rapidly than during Lassa infection, and this trend
continues during the late stage of disease. These results
support the hypothesis that the immune system re-
sponds to different viral infections via a common, early,
sustained and strong innate immune response.
Different routes of infection lead to a similar early
transcriptional response
To determine if the route of infection could alter the
early transcriptional response to Ebola virus infection,
we looked at gene expression data from a study that
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Fig. 5 Ebola-naïve and vaccinated responses to Ebola virus infection. Each line represents the average fold-change in expression (log2, y-axis) of
MX1, RSAD2, SIGLEC1, and IFIT3 at different times (x-axis) after Ebola virus infection. Panel a shows genes from Ebola-naïve macaques, and Panel
b shows genes from vaccinated animals. Panels c and d show the fold-change of SIGLEC1 and RSAD2 in vaccinated and Ebola-naïve macaques
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compared it to the intramuscular injection data. Figure 7
shows the expression of the top 20 genes (Additional file
1) that have the strongest changes 4 days post-infection in
the intramuscular group (Fig. 7a), as well as the pattern of
expression of those same genes under aerosol exposure
(Fig. 7b). RNA sequencing was used to quantify the ex-
pression in the intramuscular group, while microarrays
were used for the aerosol group. We find that both groups
show a strong increase in expression starting at 3–4 days
post-infection and increasing during the course of disease.
The average log2 fold-change in the intramuscular group
at 4 days post-infection is 6.05, and in the aerosol group at
3 days post-infection it is 2.17. Given that this difference
in magnitude takes place at different days, it is not pos-
sible to determine if the aerosol model shows a delayed re-
sponse without obtaining additional samples at these
timepoints. By 6 days post-infection, the fold change in
expression for both models is similar.
The innate immune response takes place across most
tissues
We next used the list of genes that were strongly upregu-
lated in PBMCs in the macaque intramuscular Ebola
dataset (125 genes, Additional file 1) and looked at their
expression in the macaque aerosol Ebola dataset. We
found that 88 % of the genes from the intramuscular list
showed strong upregulation in the aerosol model (111
genes, Additional file 2). We also looked at the expression
of these genes in the remaining tissues in the aerosol
model and found that the early immune response is
present across most tissues at varying magnitudes and ex-
pression rates. Figure 8 shows the average expression rate
of these genes across each tissue type. PBMCs become
transcriptionally activated at 6 days post-infection, and
show the strongest activation compared to the remaining
tissues at 7 days post-infection. Liver starts becoming tran-
scriptionally activated 3 days post-infection and the aver-
age expression level continues to increase by 5 and 8 days
post–infection. The gene expression response in the spleen
begins to increase at day 3 and also increases to similar
levels as in the liver. In the adrenal gland and the pancreas,
the expression level increases at 4 days post-infection and
remains activated until the end of the infection. The axil-
lary lymph node is the last to become activated, starting
around day 6. The brain shows the lowest levels of activa-
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Fig. 6 Changes in expression of interferon-stimulated genes during different hemorrhagic fever infections. Each line represents the average fold-change
in expression (log2, y-axis) of MX1, ISG15, DHX58 or OAS1 at different times (x-axis) after Ebola, Lassa or Marburg virus infection
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Discussion
Our analysis of the transcriptomic response to Ebola
virus infection highlights that there is a strong activation
of innate immune response genes at early times post-
infection, most of which are classified as interferon-
stimulated genes. This finding is consistent with other
analyses of host responses to different viral infections
[14, 24, 41] and with an earlier report [12]. These find-
ings highlight a strong contrast between in vitro studies
of Ebola virus function. Previous studies have shown that
Ebola virus infection in vitro blocks the expression of
ISGs in liver cells [7, 8]. This interferon-antagonism is
based on the ability of VP35 to block the activation of
IRF3, which inhibits the expression of interferon beta
and other ISGs. Mutation of VP35 in a manner that al-
lows IRF3 signaling has been studied in mice [10] and
guinea pigs [11] using a recombinant Ebola strain con-
taining a single-point mutation in VP35 (R322A). This
mutation reduced the virus’s ability to replicate and to
block interferon signaling in vitro; in vivo, this virus did
not cause pathogenesis in these animal models. These
studies are consistent with the hypothesis that Ebola
virus causes a systemic inhibition of the interferon re-
sponse [42].
A caveat of these earlier studies is that they did not
measure the innate immune response in the animals
during Ebola virus infection to determine if there was an
observable change in interferon-induced signaling in the
animal model as well. Our analysis found that mice in-
fected with both pathogenic and non-pathogenic EBOV
show a strong expression of interferon-stimulated genes
in the spleen. The fact that strong interferon responses













































































Fig. 7 Aerosol infection shows a delayed transcriptional response. Each line represents the average fold-change in expression (log2, y-axis) of one
of 20 top genes at different times (x-axis) after Ebola virus infection. Panel a corresponds to intramuscular injection (quantified using RNA sequencing),
and Panel b to aerosol exposure (quantified using microarrays). Panels c and d illustrate the delay observed in two individual genes (ISG15 and IFIT2) in
the aerosol and intramuscular groups
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occur in mice infected with non-pathogenic WT-EBOV
is perhaps not surprising, as the non-adapted virus
would be expected to induce a strong innate immune re-
sponse. That the same response was seen in pathogenic
MA-EBOV infected mice argues that a robust innate im-
mune response in the spleen is generated in response to
both pathogenic and non-pathogenic EBOV infection in
mice. It was reported that in the mouse model the WT-
EBOV showed strongly attenuated and delayed growth,
while the MA-EBOV showed strong growth [9], perhaps
suggesting that the non-mouse adapted virus was sup-
pressed by innate signaling while the pathogenic virus
was not.
This observation that innate immune genes are upreg-
ulated in the mouse-model of EVD is consistent with
earlier reports suggesting that primary cells exposed to
Ebola virus strongly activate interferon-like signaling
[43] and data showing that in NHP-infection interferon-
like signaling is upregulated [12, 38]. Together, the find-
ings from two different model systems imply that innate
signaling is largely unimpeded during Ebola virus infec-
tion and would be observed in human disease as well.
Either IRF3 is activated or interferon is expressed and
released into the circulation leading to an early, and glo-
bal innate response in vivo. Additional experiments are
needed to determine why we detect a significant increase
in the expression of interferon-stimulated genes at the
early stages of Ebola virus infection. One explanation
could be that infected cells stimulate uninfected neigh-
boring cells to produce interferon through a currently
unknown mechanism, and that this stimulates them to
express ISGs and to continue spreading the interferon
signal (Fig. 9a). Since we see viral titers and ISG expres-
sion increasing throughout infection, further studies are
required to understand if the populations of cells that
are expressing ISGs are different from the ones that are
undergoing viral replication. Another hypothesis is that,
in vivo, some cells may retain their ability to translocate
IRF3 to the nucleus and to express interferon, perhaps
due to a missing VP35 (Fig. 9b). This is consistent with
earlier reports showing that there are early immune-
associated transcriptional responses in primary target
cells exposed to either Ebola virions or virus-like parti-
cles (VLPs) [44, 45].
One of the hallmarks of Ebola virus infection is dys-
regulated levels of circulating proinflammatory cyto-
kines. We observed the levels of expression of previously
reported cytokines such as IL6, and CXCL8 (IL8) in-
crease between 4 and 7 days post-infection. We also
found several cytokines, such as CCL7 and CXCL11 (I-
TAC), that showed significant changes in expression but
whose protein levels have not been previously observed
during Ebola pathogenesis. CXCL10 (IP-10) and CXCL11
were two of the cytokines that were expressed in animals
that succumb to infection. Interestingly, we saw a signifi-
cant increase in expression in vaccinated macaques in-
fected with Ebola virus. This suggests that they are part of
a conserved response in both the pathogenic and non-
pathogenic response to Ebola virus. Both cytokines are
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Fig. 8 Innate transcriptional response in tissues in an aerosol macaque model of infection. Black lines represent the average expression across all
tissues for the 111 genes most highly expressed in PBMCs (grey line). The y-axis represents log10 read counts per million, and the x-axis different
times after infection. Statistically significant differences at matching time points are highlighted with (*)
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common receptor (CXCR3), and are thought to be in-
volved in the recruitment of effector T cells and NK cells
[46]. They are also known to be induced during the acute
phase in other types of viral infections including dengue
[47], influenza [48], hepatitis B and C [49, 50], Herpes
simplex [51] and HIV-1 [52]. Upregulation of CXCL10
has also been associated with hemorrhagic manifestations
in patients infected with Sudan virus [34]. Our observa-
tions suggest that these cytokines are part of a core innate
immune response that is triggered in all animals exposed
to Ebola virus, but that they are overexpressed in animals
that will succumb to disease.
By comparing how different routes of infection affect
the cellular circulating immune response in Ebola virus-
infected primates, we observed that infection via an
aerosol and via intramuscular injection resulted in simi-
lar patterns of gene expression. Previous studies have
reported a delay in the aerosol model of exposure com-
pared to the intramuscular model [53], but given that we
do not have samples from both infections taken at iden-
tical early time points, we were not able to confirm this
observation.
Conclusions
Infection with Ebola virus leads to early and robust
interferon-like responses that take place before the ap-
pearance of virus in the blood. This response takes place
not only on circulating immune cells, but throughout
the majority of infected tissues. Our results extend earl-
ier observations of a strong innate immune response
and suggest the involvement of new cytokines in Ebola
virus infection. Further analysis of the cells responsible
for driving this response, and for producing the different
cytokine signals, will be important to understand the
ability of the virus to replicate virtually unchecked in
many tissues—even when these tissues show a strong
interferon-expression signal—, and to identify which
cells are undergoing an uncontrolled ISG response.
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Fig. 9 Model for the expression of interferon-stimulated genes during Ebola virus infection. a Ebola-infected cell (top) is not able to produce
interferon due to the VP35-inhibition of IRF3 translocation. We suggest that the infected cell, through an unknown mechanism, might be able to
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cells, it activates the receptors of additional cells (bottom) and leads to the transcription of ISGs. b An alternative model is that some cells (top)
can become infected with Ebola VLPs, which are not able to block IRF3 translocation, and therefore they can produce interferon, release it to
neighboring cells (middle and bottom) and they in turn start transcribing ISGs
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